TLIS talis.bio Projected Price to Earnings

Corporate company logo of Talis Biomedical (TLIS)

The lack of payments is due to insurance coverage complexities and the slow adoption of new platforms. The change in the forward P/E ratio for Talis Biomedical (TLIS) on the GURU.Markets daily chart shows that the parameter reaches 0.00. This accompanies the development of partnerships with laboratories for rapid diagnostics, although the full liquidation of assets and cessation of operations have effectively removed the business from market competition.

TLIS - Talis Biomedical Market Cap to Projected Earnings over the range 07/04/2022 - 09/07/2024

Financial and market metric breakdowns for Talis Biomedical Corp (TLIS)

- stock value and consensus price forecast:
Price Chart Talis Biomedical|TLIS - Analyst Median Target
- market capitalization data:
Market Valuation Talis Biomedical Corp.|TLIS - Aggregate Business Value
- issuer book value statistics:
Book Value per Share Talis Biomedical|TLIS - Book Valuation of Business|Market Capitalization to Book Value Ratio talis.bio|TLIS - Cumulative Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Talis Biomedical|TLIS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Talis Biomedical|TLIS - Company Total Debt|Debts to Book Capitalization Talis Biomedical Corp.|TLIS - Long-Term Debt|Company Short-Term Debts Talis Biomedical|Quick Ratio talis.bio
- earnings and market ratios statistics:
TLIS - Net Financial Result|Projected Future Earnings Talis Biomedical|TLIS - Price to Earnings Ratio|Forward P/E Multiple Talis Biomedical|TLIS - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Talis Biomedical Corp.|TLIS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Talis Biomedical|TLIS - Earnings per share for the trailing year|Quarterly EPS earnings growth talis.bio|TLIS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Talis Biomedical
Fundamental company analysis:Talis Biomedical Corporation
Product sample of Talis Biomedical

Forward P/E reflects market expectations for future earnings, allowing for the valuation of one dollar of expected income amid the Fed's tight monetary policy. While investors analyze future P/E multiples to determine a growth premium, this metric becomes meaningless for Talis Biomedical (TLIS) due to the liquidation of the business and the complete cessation of operating activities.

Competitors of Talis Biomedical (TLIS)

Future Price to Earnings Abbott (ABT)|Market Cap to Projected Earnings Thermo Fisher Scientific Inc.|GE Healthcare Corp - Projected Price to Earnings|Market Cap to Future Earnings Ratio MTD (Mettler Toledo Inc)|Waters Corporation - Forward P/E Multiple|Market Cap to Projected Earnings bio-techne.com TECH|BRKR: Forward P/E Multiple|Projected Price to Earnings Azenta Inc|Projected Price to Earnings VREX|SMLR: Future Price to Earnings Multiple|Future Price to Earnings Butterfly Network, Inc. (BFLY)|Projected Price to Earnings mesalabs.com MLAB|Forward P/E Multiple QSI (Quantum-Si Incorporated)|Nano-X Imaging (NNOX) - Projected Price to Earnings Ratio|Quanterix Corp - Forward P/E Multiple|MASS (908 Devices Corporation) - Price to Future Earnings Ratio|CV: Forward P/E Multiple|MXCT - Market Cap to Projected Earnings|RPID (Rapid Micro Biosystems Inc.) - Forward P/E Multiple|Projected Price to Earnings Seer Inc (SEER)|Forward P/E Multiple HYPR|Forward P/E Multiple FONAR Corporation Inc (FONR)|Future Price to Earnings Daxor DXR|Spectral AI Inc. - Future Price to Earnings|VIVS: Projected Price to Earnings|Future Price to Earnings Multiple ACON (Aclarion Inc)|AKYA: Forward P/E Multiple|Projected Price to Earnings Ratio Cesca Therapeutics (THMO)|Future Price to Earnings T2 Biosystems, Inc.